Gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: A meta-analysis

Journal of Magnetic Resonance Imaging

Volumn 39, Issue 5, 2014, Pages 1079-1087

  Lei, Junqiang ^a   Wang, Yinzhong ^a   Li, Zhang ^a   Guo, Shunlin ^a   Wang, Xiaohui ^a   Zhai, Yanan ^a   Yang, Kehu ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

gadoxetic acid disodium; Gd EOB DTPA; HCC; hepatocellular carcinoma; meta analysis; Primovist

Indexed keywords

GADOXETIC ACID; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ALCOHOL LIVER CIRRHOSIS; ARTICLE; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; LIVER CELL CARCINOMA; MAGNETIC FIELD; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC USE; FEMALE; INTERNATIONAL COOPERATION; LIVER NEOPLASMS; MALE; OBSERVER VARIATION; PATHOLOGY; PREVALENCE; PROCEDURES; REPRODUCIBILITY; RISK FACTOR;

CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; INTERNATIONALITY; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; OBSERVER VARIATION; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84898401875     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.24354     Document Type: Article

References (26)

1. Parkin DM, Pisani P, Ferlay J,. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64, 31.
2. Gadoxetate disodium: label and approval history. U.S. Food and Drug Administration website. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.Label-ApprovalHistory#apphist. Updated September 6, 2010. Accessed September 6, 2010.
3. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792.
4. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200: 59-67.
5. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275.
6. Battaglia M, Bucher H, Egger M, et al. The Bayes Library of Diagnostic Studies and Reviews, 2nd ed. Basel, Switzerland: University of Basel; 2002.
7. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J,. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
9. Dwamena B,. MIDAS: Stata module for meta-analytical integration of diagnostic test accuracy studies. Statistical Software Components, 2009. Available at: http://fmwww.bc.edu/repec/bocode/m/midas.ado
10. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY,. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459-466.
11. Akai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol 2011; 80: 310-315.
12. Baek CK, Choi JY, Kim KA, et al. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol 2012; 67: 148-156.
13. Blondin D, Erhardt A, Crynen K, et al. Diagnosis of focal liver lesions in cirrhotic patients: comparison of contrast-enhanced ultrasound using sulphur hexafluoride (SF6) microbubbles and MRI using Gd-EOB-DTPA. Zeit Gastroenterol 2011; 49: 23-29.
14. Filippone A, Cianci R, Patriarca G, et al. The value of gadoxetic acid-enhanced hepatospecific phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Eur J Clin Med Oncol 2010; 2: 1.
15. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L,. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (<=2 cm) HCC in cirrhosis. Eur Radiol 2011; 21: 1233-1242.
16. Granito A, Galassi M, Piscaglia F, et al. Impact of gadoxetic acid (GD-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma. J Hepatol 2011; 54: S386-S387.
17. Kim SH, Kim SH, Lee J, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. Am J Roentgenol 2009; 192: 1675-1681.
18. Ooka Y, Kanai F, Okabe S, et al. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging 2012; 31: 748-754
19. Sano K, Ichikawa T, Motosugi U, et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011; 261: 834-844.
20. Sugimoto K, Moriyasu F, Shiraishi J, et al. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol 2012; 22: 1205-1213.
21. Higgins JPT, Altman DG,. Assessing risk of bias in included studies. In:, Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions, ver. 5.1.0. The Cochrane Collaboration; Updated March 2011. Available at: http://www.cochrane-handbook.org, 2011.
22. Deeks JJ,. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001; 323: 157-162.
23. Egger M, Smith GD, Altman DG, (eds.). Systematic reviews in health care: meta-analysis in context. London: BMJ Publishing Group; 2008. p 248-282.
24. Jaeschke R, Guyatt G, Lijmer J,. Diagnostic tests. In:, Guyatt G, Rennie D, eds. Users' guides to the medical literature: a manual for evidence-based clinical practice. Chicago: AMA Press; 2002. p 121-140.
25. Beardsell A, Bell S, Robinson S, Rumbold H,. MCEM Part A:MCQs. London: Royal Society of Medicine Press; 2009.
26. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM,. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-1135.